Survey Finds Lower Alcohol Intake on GLP-1 Drugs
A Harvard study published in JAMA Psychiatry reports that nearly half of adult drinkers reduced their alcohol consumption after starting a GLP-1 medication.
Survey Examines Drinking Habits on GLP-1 Medications
Nearly half of adult drinkers using glucagon-like peptide-1 (GLP-1) medications reported drinking less alcohol after starting the drugs. Researchers from Harvard Medical School (HMS), McLean Hospital, Brown University, Duke University, Brandeis University, and the RAND Corporation evaluated responses from RAND's American Life Panel collected in March and April 2026. The study was published in the journal JAMA Psychiatry.
The investigation was designed to capture population-level patterns after numerous patients reported diminished alcohol cravings while using GLP-1 medications for diabetes or weight management. Of the 2,009 adults who completed the initial panel survey, 368 reported current or past use of GLP-1 medications, and 242 confirmed they drank alcohol when they first began the medication.
Reported Drops in Alcohol Intake
Among the 242 respondents who were active drinkers when starting a GLP-1 medication, 44.2 percent (106 people) reported that they consumed less alcohol. Most of the remaining participants noted no change in their drinking habits, while three individuals reported drinking more.
The survey also applied a single-question screen for heavy drinking, based on National Institutes of Health (NIH) criteria of four drinks in a single day for women or five drinks for men during the prior year. Among the respondents meeting this threshold for potentially unhealthy drinking, 54.1 percent reported consuming less alcohol after beginning a GLP-1 medication. In that same at-risk group, 40.2 percent reported no change, and 5.7 percent (three individuals) reported drinking more.
Underuse of Existing Alcohol Treatments
Existing medications approved specifically for alcohol use disorder remain heavily underused in clinical practice. The study grew out of prior research by senior author Haiden Huskamp and co-author Alisa Busch exploring why established therapies fail to reach patients who could benefit from them.
Medications such as disulfiram have existed since the 1940s, yet national survey data indicates only 3 percent to 5 percent of individuals with a past alcohol abuse disorder report using them. Furthermore, only 10 percent of people seeking treatment receive an approved medication. The researchers noted that patient awareness regarding reduced alcohol consumption on GLP-1 medications also remains low.
Key Limitations and Missing Clinical Data
The findings come from a self-reported observational survey rather than a randomized controlled trial (RCT) designed to measure therapeutic efficacy. The researchers emphasized that the screening question identified potential heavy drinking patterns, not a formal diagnosis of clinical alcohol use disorder.
The survey also did not measure the specific volume or magnitude of the reduction in drinking. Busch and Huskamp cautioned that clinical trials are necessary before considering GLP-1 medications as targeted treatments for alcohol use disorders. Individuals with questions about alcohol use and prescription medications should speak directly with their prescribing clinician.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.


Related Articles
Obesity Drugs and Brain Protection: What the Evidence Shows
A review in Science analyzes whether obesity drugs like semaglutide protect brain function,...
Read article MetabolismWegovy Pill Approved by Australian Regulators for Weight Management
Australia's Therapeutic Goods Administration approved Wegovy tablets for weight management,...
Read article MetabolismInjectable Hydrogel Reverses Liver Fat in Animal Study
A preclinical study shows an injectable hydrogel reduces hepatic lipid accumulation and...
Read article MetabolismStanford Study Identifies BRP as AI-Found Appetite Suppressant
Stanford researchers used artificial intelligence to identify BRP, a natural peptide that...
Read articleWant medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.